Clinical Trials Logo

Clinical Trial Summary

The investigators will conduct an 8-week, non-randomized, open-label study of brexpiprazole in 20 persons with bipolar I or II disorder, depressed mood state. Primary aim will be to assess if brexpiprazole is associated with a reduction in depressive symptom severity using the Montgomery-Asberg Depression Rating Scale (MADRS). Secondary aims will include an assessment of the following in patients with bipolar disorder taking brexpiprazole: manic symptoms, cognition, safety and tolerability of brexpiprazole, and quality of life.

Subjects will be discontinued from the study if any of the following conditions occurs: change in diagnosis to other than bipolar I or II disorder, development of active suicidal or homicidal ideation with plan and intent, worsening of mood symptoms, that in the opinion of the investigators requires discontinuation, pregnancy, development of severe life-threatening medical condition, involuntary psychiatric hospitalization or incarceration.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03427892
Study type Interventional
Source University of Texas Southwestern Medical Center
Contact
Status Completed
Phase Phase 4
Start date March 1, 2017
Completion date March 15, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Active, not recruiting NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Active, not recruiting NCT02363738 - 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression Phase 2
Terminated NCT01807741 - Asenapine for Bipolar Depression Phase 2
Recruiting NCT01213121 - Neurophysiologic Changes in Patients With Bipolar Depression Phase 4
Completed NCT01919892 - Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium Phase 4
Completed NCT00762268 - A Trial of SAMe for Treatment-Resistant Bipolar Depression N/A
Recruiting NCT00566111 - Ceftriaxone in the Management of Bipolar Depression N/A
Terminated NCT00217217 - Low Field Magnetic Stimulation Treatment for Bipolar Depression Phase 3
Completed NCT02088580 - Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients N/A
Terminated NCT00272025 - Treatment Resistant Bipolar Depression Phase 1
Completed NCT00566150 - Levetiracetam in the Management of Bipolar Depression N/A
Completed NCT01284517 - Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression Phase 3
Completed NCT00988949 - Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release Phase 1
Terminated NCT00805493 - Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder Phase 2
Completed NCT00789113 - Determination of Absorption and Elimination of Lamotrigine-XR Phase 1/Phase 2
Completed NCT00562861 - Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram Phase 2/Phase 3
Completed NCT00578383 - Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device N/A
Active, not recruiting NCT02989727 - Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine Phase 4
Recruiting NCT03249376 - Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally Phase 3